// App-Quantinova.ai

3217 : MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART) protein with T-cell immunomodulatory activity for cancer treatment

Researchers

Presenter

  • Ross LaMotte-Mohs

Principal Investigators

  • Doug Smith

  • Sergey Gorlatov

  • Valentina Ciccarone

  • James Tamura

  • Hua Li

  • Jill Rillema

  • Monica Licea

  • Leilei He

  • Farha Vasanwala

  • Wei Chen

  • Xiao-Tao Yao

  • Francine Chen

  • Jennifer Brown

  • Jeffrey Nordstrom

  • Scott Koenig

  • Ezio Bonvini

  • Syd Johnson

  • Paul Moore

Medical Centers

  • MacroGenics, Inc., Rockville, MD

  • MacroGenics, Inc, South San Francisco, CA

Locations

  • United States

Companies

  • MacroGenics, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved